JP2016510329A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510329A5 JP2016510329A5 JP2015553933A JP2015553933A JP2016510329A5 JP 2016510329 A5 JP2016510329 A5 JP 2016510329A5 JP 2015553933 A JP2015553933 A JP 2015553933A JP 2015553933 A JP2015553933 A JP 2015553933A JP 2016510329 A5 JP2016510329 A5 JP 2016510329A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- aqueous pharmaceutical
- corticosteroid
- thickener
- acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 54
- 239000003246 corticosteroid Substances 0.000 claims description 42
- 239000002562 thickening agent Substances 0.000 claims description 21
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 11
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 11
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical group [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 11
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 229960001334 corticosteroids Drugs 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 229960005294 triamcinolone Drugs 0.000 claims description 8
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 8
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 claims description 7
- 229960003657 dexamethasone acetate Drugs 0.000 claims description 7
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 claims description 5
- 230000003444 anaesthetic effect Effects 0.000 claims description 5
- 229960003957 dexamethasone Drugs 0.000 claims description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 5
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 claims description 5
- 229920002674 hyaluronan Polymers 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- 229960004584 methylprednisolone Drugs 0.000 claims description 5
- 229960001293 methylprednisolone acetate Drugs 0.000 claims description 5
- PLBHSZGDDKCEHR-LFYFAGGJSA-N methylprednisolone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(C)=O)CC[C@H]21 PLBHSZGDDKCEHR-LFYFAGGJSA-N 0.000 claims description 5
- 229960005205 prednisolone Drugs 0.000 claims description 5
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 5
- 229960002800 prednisolone acetate Drugs 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 230000002335 preservative effect Effects 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- VOBDXTSTTMAKHK-VHDCPBDGSA-N 3870-07-3 Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O VOBDXTSTTMAKHK-VHDCPBDGSA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 229960000334 methylprednisolone sodium succinate Drugs 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 229950004597 prednisolone succinate Drugs 0.000 claims description 3
- APGDTXUMTIZLCJ-CGVGKPPMSA-N prednisolone succinate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC(O)=O)[C@@H]4[C@@H]3CCC2=C1 APGDTXUMTIZLCJ-CGVGKPPMSA-N 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 3
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 3
- 229960002537 betamethasone Drugs 0.000 claims description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 2
- AKUJBENLRBOFTD-QZIXMDIESA-N betamethasone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O AKUJBENLRBOFTD-QZIXMDIESA-N 0.000 claims description 2
- 229960004648 betamethasone acetate Drugs 0.000 claims description 2
- 229960005354 betamethasone sodium phosphate Drugs 0.000 claims description 2
- PLCQGRYPOISRTQ-LWCNAHDDSA-L betamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-LWCNAHDDSA-L 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229940083542 sodium Drugs 0.000 claims 1
- 229940074404 sodium succinate Drugs 0.000 claims 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 1
- FKKAEMQFOIDZNY-CODXZCKSSA-M prednisolone sodium succinate Chemical compound [Na+].O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC([O-])=O)[C@@H]4[C@@H]3CCC2=C1 FKKAEMQFOIDZNY-CODXZCKSSA-M 0.000 description 1
- 229960002176 prednisolone sodium succinate Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361755723P | 2013-01-23 | 2013-01-23 | |
| US61/755,723 | 2013-01-23 | ||
| US201361776617P | 2013-03-11 | 2013-03-11 | |
| US61/776,617 | 2013-03-11 | ||
| PCT/US2014/012824 WO2014116876A1 (en) | 2013-01-23 | 2014-01-23 | Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510329A JP2016510329A (ja) | 2016-04-07 |
| JP2016510329A5 true JP2016510329A5 (enExample) | 2017-02-09 |
| JP6215354B2 JP6215354B2 (ja) | 2017-10-18 |
Family
ID=50097866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015553933A Active JP6215354B2 (ja) | 2013-01-23 | 2014-01-23 | 不溶性コルチコステロイドおよび可溶性コルチコステロイドを含む医薬処方物 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US9833460B2 (enExample) |
| EP (1) | EP2948182B1 (enExample) |
| JP (1) | JP6215354B2 (enExample) |
| KR (1) | KR102055937B1 (enExample) |
| CN (1) | CN105073138B (enExample) |
| AU (2) | AU2014209346B2 (enExample) |
| BR (1) | BR112015017246B1 (enExample) |
| CA (1) | CA2897467C (enExample) |
| IL (1) | IL239791B (enExample) |
| MX (1) | MX366654B (enExample) |
| NZ (1) | NZ709620A (enExample) |
| TW (1) | TWI624262B (enExample) |
| WO (1) | WO2014116876A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2336117A1 (en) | 2005-05-26 | 2011-06-22 | Neuron Systems, Inc | Heterocyclic compounds for treating retinal diseases |
| WO2011072141A1 (en) | 2009-12-11 | 2011-06-16 | Neuron Systems, Inc. | Compositions and methods for the treatment of macular degeneration |
| CA2898631C (en) | 2013-01-23 | 2023-06-13 | Aldeyra Therapeutics, Inc. | Toxic aldehyde related diseases and treatment |
| NZ709620A (en) | 2013-01-23 | 2020-07-31 | Semnur Pharmaceuticals Inc | Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid |
| TWI674899B (zh) * | 2015-01-21 | 2019-10-21 | 美商桑紐爾製藥公司 | 醫藥配方 |
| WO2016191820A1 (en) * | 2015-06-02 | 2016-12-08 | Newsouth Innovations Pty Limited | Formulation and process for limiting nerve trauma |
| CN108135907A (zh) | 2015-08-21 | 2018-06-08 | 奥尔德拉医疗公司 | 氘化化合物和其用途 |
| US11129823B2 (en) | 2016-05-09 | 2021-09-28 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
| MX2020003425A (es) | 2017-10-10 | 2020-07-29 | Aldeyra Therapeutics Inc | Tratamiento de trastornos inflamatorios. |
| EP3833660A4 (en) | 2018-08-06 | 2022-05-11 | Aldeyra Therapeutics, Inc. | POLYMORPHIC COMPOUNDS AND THEIR USES |
| JP2022511030A (ja) * | 2018-12-05 | 2022-01-28 | アルデイラ セラピューティクス， インコーポレイテッド | 注射可能な製剤 |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| CA3137301A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| US11382863B2 (en) * | 2020-03-04 | 2022-07-12 | Somerset Therapeutics Llc | Injectable suspension comprising an insoluble corticosteroid and a soluble corticosteroid |
| WO2021231792A1 (en) | 2020-05-13 | 2021-11-18 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
| CA3199093A1 (en) * | 2020-10-22 | 2022-04-28 | Pfizer Inc. | Peg-free aqueous suspensions for parenteral administration of a corticosteroid |
| WO2024159191A1 (en) * | 2023-01-26 | 2024-08-02 | Insignia Pharmaceuticals, Llc | Pharmaceutical compositions for treating osteoarthritis |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL25251A (en) | 1965-07-20 | 1969-11-12 | Merck & Co Inc | Aqueous mixtures for ophthalmology based on hydroxyethylcellulose and a method for their preparation |
| US3962430A (en) * | 1974-08-07 | 1976-06-08 | Merck & Co., Inc. | Sterilization of solid non-electrolyte medicinal agents employing sodium chloride |
| US4304765A (en) | 1980-10-14 | 1981-12-08 | Alza Corporation | Ocular insert housing steroid in two different therapeutic forms |
| EP0244178A3 (en) | 1986-04-28 | 1989-02-08 | Iolab, Inc | Intraocular dosage compositions and method of use |
| IL80298A (en) | 1986-10-14 | 1993-01-31 | Res & Dev Co Ltd | Eye drops |
| FI105075B (fi) | 1996-01-10 | 2000-06-15 | Suprakort Oy | Kombinaatioinjektiovalmisteen käyttö |
| IT1288290B1 (it) | 1996-06-21 | 1998-09-11 | Fidia Spa In Amministrazione S | Acido ialuronico autoreticolato e relative composizioni farmaceutiche per il trattamento delle artropatie |
| JPH11279065A (ja) | 1998-03-25 | 1999-10-12 | Shiseido Co Ltd | 局所投与炎症治療剤 |
| US6921532B1 (en) * | 2000-06-22 | 2005-07-26 | Spinal Restoration, Inc. | Biological Bioadhesive composition and methods of preparation and use |
| US6747090B2 (en) * | 2001-07-16 | 2004-06-08 | Pharmacia Groningen Bv | Compositions capable of forming hydrogels in the eye |
| US20040006052A1 (en) | 2002-04-15 | 2004-01-08 | Gudas Charles J. | Injection solutions to treat neuropathic symptoms and other sensorimotor disorders that are due to neuromas of the foot or other entrapment neuropathies of peripheral nerves, and method of use |
| US20050101582A1 (en) * | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| US20070224278A1 (en) | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
| US20050186229A1 (en) | 2004-02-24 | 2005-08-25 | Emmett Clemente | Pleasant-tasting aqueous liquid composition of prednisolone sodium phosphate |
| JP2007001926A (ja) * | 2005-06-24 | 2007-01-11 | Ltt Bio-Pharma Co Ltd | 吸入・噴霧用ステロイド製剤 |
| JP4969812B2 (ja) | 2005-07-22 | 2012-07-04 | 久光製薬株式会社 | ハイドロゲル組成物 |
| US20070099882A1 (en) | 2005-10-27 | 2007-05-03 | Gurney Harry C | Methods and compositions for prolonged alleviation of articular joint pain |
| EP1968614A2 (en) | 2005-12-14 | 2008-09-17 | Anika Therapeutics Inc. | Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid |
| US20070141160A1 (en) * | 2005-12-15 | 2007-06-21 | Brown Laura J | Method of treatment for osteoarthritis by local intra-articular injection of microparticles |
| CN100534434C (zh) * | 2006-05-15 | 2009-09-02 | 西安力邦制药有限公司 | 透明质酸钠地塞米松脂肪乳制剂及其应用 |
| US20080317805A1 (en) | 2007-06-19 | 2008-12-25 | Mckay William F | Locally administrated low doses of corticosteroids |
| US9421356B2 (en) * | 2007-08-28 | 2016-08-23 | Teikoku Pharma Usa, Inc. | Transdermal methods and systems for the delivery of corticosteroid compounds |
| US20090143348A1 (en) | 2007-11-30 | 2009-06-04 | Ahmet Tezel | Polysaccharide gel compositions and methods for sustained delivery of drugs |
| US20090143807A1 (en) | 2007-12-03 | 2009-06-04 | Vertos Medical, Inc., A Delaware Corporation | Percutaneous Devices for Separating Tissue, Kits and Methods of Using the Same |
| JP2011513337A (ja) * | 2008-04-18 | 2011-04-28 | ウォーソー・オーソペディック・インコーポレーテッド | 椎間板ヘルニアを治療するための方法および組成物 |
| WO2009139924A2 (en) * | 2008-05-14 | 2009-11-19 | Otonomy, Inc. | Controlled release corticosteroid compositions and methods for the treatment of otic disorders |
| EP2365812A4 (en) * | 2008-11-10 | 2012-05-16 | Nitric Biotherapeutics Inc | PHARMACEUTICAL FORMULATIONS FOR THE IONTOPHORETIC DELIVERY OF A CORTICOSTEROID |
| AU2010276574B2 (en) * | 2009-07-30 | 2015-08-20 | Carbylan Therapeutics, Inc. | Modified hyaluronic acid polymer compositions and related methods |
| UA111162C2 (uk) | 2010-08-04 | 2016-04-11 | Флекшен Терап'Ютікс, Інк. | Ін'єкційна композиція ацетоніду триамцинолону для лікування болю |
| RU2459615C1 (ru) | 2011-03-05 | 2012-08-27 | Илья Александрович Марков | Глазные капли для лечения болезни сухого глаза |
| BR112014012885A2 (pt) | 2011-12-06 | 2017-06-13 | Alcon Res Ltd | composição de gel celulósica com estabilidade de viscosidade aperfeiçoada |
| US20130165419A1 (en) | 2011-12-21 | 2013-06-27 | Insite Vision Incorporated | Combination anti-inflammatory ophthalmic compositions |
| NZ709620A (en) | 2013-01-23 | 2020-07-31 | Semnur Pharmaceuticals Inc | Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid |
| TWI674899B (zh) | 2015-01-21 | 2019-10-21 | 美商桑紐爾製藥公司 | 醫藥配方 |
-
2014
- 2014-01-23 NZ NZ709620A patent/NZ709620A/en unknown
- 2014-01-23 AU AU2014209346A patent/AU2014209346B2/en active Active
- 2014-01-23 BR BR112015017246-6A patent/BR112015017246B1/pt active IP Right Grant
- 2014-01-23 KR KR1020157022624A patent/KR102055937B1/ko active Active
- 2014-01-23 TW TW103102506A patent/TWI624262B/zh active
- 2014-01-23 JP JP2015553933A patent/JP6215354B2/ja active Active
- 2014-01-23 WO PCT/US2014/012824 patent/WO2014116876A1/en not_active Ceased
- 2014-01-23 US US14/162,625 patent/US9833460B2/en active Active
- 2014-01-23 EP EP14704239.4A patent/EP2948182B1/en active Active
- 2014-01-23 CN CN201480005642.9A patent/CN105073138B/zh active Active
- 2014-01-23 CA CA2897467A patent/CA2897467C/en active Active
- 2014-01-23 MX MX2015009455A patent/MX366654B/es active IP Right Grant
-
2015
- 2015-07-05 IL IL239791A patent/IL239791B/en active IP Right Grant
-
2017
- 2017-10-30 US US15/798,053 patent/US10744144B2/en active Active
-
2019
- 2019-01-31 AU AU2019200649A patent/AU2019200649B2/en active Active
-
2020
- 2020-07-06 US US16/921,628 patent/US11364251B2/en active Active
-
2022
- 2022-05-11 US US17/741,729 patent/US12016867B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10278928B2 (en) | Film-forming pharmaceutical composition for wound healing and method for preparing the same | |
| EP1682185B1 (en) | Compositions and methods for treating a posterior segment of an eye | |
| JP2018502872A5 (enExample) | ||
| JP2011520899A5 (enExample) | ||
| WO2011106702A3 (en) | Sustained delivery of therapeutic agents to an eye compartment | |
| JP2015024174A5 (enExample) | ||
| JP2016534141A5 (enExample) | ||
| EA201591560A1 (ru) | Инъекционная композиция с контролируемым высвобождением, содержащая жидкий носитель с высокой вязкостью | |
| JP2017513809A5 (enExample) | ||
| MX337364B (es) | Formulaciones farmaceuticas de azol para la administracion parenteral y metodos para preparar y usar las mismas como tratamiento de las enfermedades sensibles a los compuestos de azol. | |
| TWI674899B (zh) | 醫藥配方 | |
| JP2016526039A5 (enExample) | ||
| SA517390331B1 (ar) | تراكيب مصفوفة بوليمر موضعية تشتمل على تركيز عالي من هيالورونات الصوديوم المخمر حيوياً واستخداماتها | |
| JP2016517421A5 (enExample) | ||
| JP2018510894A5 (enExample) | ||
| WO2014160155A3 (en) | Implantable drug delivery compositions comprising non-polymeric sorption enhancers and methods of treatment thereof | |
| IL309340A (en) | Dosing regimen for missing doses of paliperidone long-acting injectable esters | |
| JP2017503828A (ja) | 皮膚及び粘膜を局所処置するための、多価アルコール及びコレカルシフェロールを含む組成物 | |
| RU2017129375A (ru) | Интестинальный гель на основе леводопы и карбидопы и способы его применения | |
| JP2018516910A5 (enExample) | ||
| JP2015504094A5 (enExample) | ||
| JP2021505550A5 (enExample) | ||
| KR101304341B1 (ko) | 코르티코스테로이드, 항히스타민제 및 β-사이클로덱스트린을 포함하는, 안정성이 개선된 약학 조성물 | |
| BR112022003687A2 (pt) | Método para tratar tinnitus, composição farmacêutica para administração intranasal, e, dose unitária pulverizável de ocitocina | |
| TWI801053B (zh) | 眼用組合物 |